Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Thiourea-based gemfibrozil analogues as HDL-elevating agents.

Gary M Coppola¹, Robert E Damon, J Bruce Eskesen

¹Department of Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA. gary.coppola@pharma.novartis.com

Bioorganic & Medicinal Chemistry Letters

|August 6, 2002

Summary

Researchers developed new gemfibrozil analogues containing a thiourea group to boost high-density lipoprotein (HDL) cholesterol. Several derivatives demonstrated efficacy comparable to gemfibrozil in raising HDL levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.

ACS medicinal chemistry letters·2020

Same author

Discovery of an Orally Bioavailable Benzimidazole Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor That Suppresses Body Weight Gain in Diet-Induced Obese Dogs and Postprandial Triglycerides in Humans.

Journal of medicinal chemistry·2017

Same author

Intestinally Targeted Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors Robustly Suppress Postprandial Triglycerides.

ACS medicinal chemistry letters·2014

Same author

Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.

Journal of medicinal chemistry·2012

Same author

Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.

Molecular cancer therapeutics·2011

Same author

Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197.

The Journal of biological chemistry·2011

Area of Science:

Medicinal Chemistry
Pharmacology
Cardiovascular Research

Background:

Gemfibrozil is a lipid-regulating drug used to manage dyslipidemia.
Elevating high-density lipoprotein (HDL) cholesterol is a therapeutic goal for reducing cardiovascular risk.
Novel compounds are sought to improve lipid profiles and cardiovascular outcomes.

Purpose of the Study:

To synthesize and evaluate novel gemfibrozil analogues.
To investigate the potential of thiourea-containing compounds as HDL-elevating agents.
To compare the efficacy of new analogues with gemfibrozil.

Main Methods:

Synthesis of gemfibrozil analogues incorporating a thiourea moiety in the side chain.
In vitro and/or in vivo evaluation of the synthesized compounds.

Related Experiment Videos

Assessment of HDL cholesterol-elevating capacity.

Main Results:

Successful preparation of a series of gemfibrozil analogues.
Identification of derivatives 8b, 9b, 9c, and 9d as effective HDL-elevating agents.
Demonstration that these derivatives exhibit efficacy similar to gemfibrozil.

Conclusions:

The synthesized thiourea-containing gemfibrozil analogues show promise as HDL-elevating agents.
These novel compounds represent potential therapeutic candidates for managing lipid disorders.
Further research may elucidate their detailed mechanism of action and clinical utility.